Pendulum Therapeutics

Pendulum Therapeutics is a biotechnology company based in San Francisco, California, founded in 2012.

The company focuses on microbiome science and has developed the first clinically proven probiotic aimed at supporting metabolic health and managing type 2 diabetes. Their flagship product, Pendulum Glucose Control, is a medical probiotic that has been shown to lower A1C and blood glucose spikes in individuals with type 2 diabetes. The company utilizes evidence-based microbiome science and advanced DNA sequencing to create targeted interventions for chronic diseases. Pendulum is notable for being the only brand in the U.S. to offer live *Akkermansia*, a bacterial strain that helps regulate blood sugar by stimulating natural GLP-1 production. Pendulum Therapeutics aims to improve the lives of those with type 2 diabetes and others interested in enhancing their metabolic and gut health through innovative, accessible solutions.